66
Participants
Start Date
February 26, 2020
Primary Completion Date
September 30, 2025
Study Completion Date
July 31, 2027
Niraparib
Niraparib: 200 mg, oral, once daily, days 1-21
dostarlimab
dostarlimab: 500 mg IV, every three weeks for 4 cycles followed by 1000 mg every six weeks for up to two years
University of Virginia Cancer Center, Charlottesville
Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
Louisiana State University Health Science Center, New Orleans
Stephenson Cancer Center, Oklahoma City
Tesaro, Inc.
INDUSTRY
University of Oklahoma
OTHER